Method and Compound for Modifying Circadian Clock

Abstract

Circadian rhythm is modulated by administering a circadian rhythm phase-shifting hPER2 phosphorylating kinase inhibitor.

Claims

1. A method of modulating circadian rhythm comprising administering to a subject in need thereof an hPER2 phosphorylating kinase inhibitor.

2. (canceled)

3. A composition comprising (a) an hPER2 phosphorylating kinase inhibitor, and (b) a different medicament for treating jet lag, shift-work or age-related sleep disturbances.

4. The method, of claim 1, wherein the kinase is selected from: CDK5, PRKACB, PRKG1, IKBKB, TSSK2 and IKBKE.

5. The method, compound or composition of any of claim 1, wherein the kinase and inhibitor are selected from: (a) CDK5 and Dinaciclib , Cdk/crk inhibitor, Roscovitine or Indirubin-3monoxime-5-sulphonic acid, 9-Cyanopaullone; (b) IKBKB and Ikk2 inhibitor iv, Ikk2 inhibitor v, Ikk2 inhibitor vi or AS602868; and (c) IKBKE and Cayl0576.

6. The method, compound or composition of any of claim 1, wherein the inhibitor is in unit dosage form.

7. The composition of claim 3 wherein the inhibitor and medicament are copackaged or coformulated.

8. The composition of claim 3 wherein the medicament is caffeine, melatonin, zolpidem, eszopiclone, zaleplon or triazolam.

9. The method of claim 1 wherein the subject is a person exposed or determined to be at risk of exposure to jet lag, shift-work or age-related sleep disturbances.

10. The method of claim 1 further comprising the antecedent step of determining the subject is exposed or at risk of exposure to jet lag, shift-work or age-related sleep disturbances.

11. A method of detecting a modulator of a mammalian intracellular clock comprising: a) kinase assaycontacting a kinase with a compound and detecting a resultant inhibition of the kinase; and b) clock assaycontacting the mammalian clock with the compound and detecting a resultant modulation of the clock.

12. The method of claim 11 wherein the kinase assay is in vitro or cell-based, and the clock assay is cell- or animal-based.

13-15. (canceled)

16. The method, compound or composition of any of claim 1, wherein the hPER2 phosphorylating kinase inhibitor is dinaciclib, and the dinaciclib is at a: (a) dosage that is subtherapeutic for cancer treatment; (b) dosage that is less than 50%, 20% or 10% of therapeutic or conventional cancer dosage; (c) dosage that is less than 1 or 2 or 5 or 10 or 20 mg/m.sup.2; or (d) unit dosage form of less than 1, 2, 5, 10 or 20 mg. 17-21. (Canceled)

22. The composition of claim 3, wherein the kinase is selected from: CDKS, PRKACB, PRKG1, IKBKB, TSSK2 and IKBKE.

23. The composition of claim 3, wherein the kinase and inhibitor are selected from: (a) CDK5 and Dinaciclib, Cdk/crk inhibitor, Roscovitine or Indirubin-3monoxime-5-sulphonic acid, 9-Cyanopaullone; (b) IKBKB and Ikk2 inhibitor iv, Ikk2 inhibitor v, Ikk2 inhibitor vi or AS602868; and (c) IKBKE and Cayl0576.

24. The composition of claim 3, wherein the inhibitor is in unit dosage form.

25. The composition of claim 3, wherein the hPER2 phosphorylating kinase inhibitor is dinaciclib, and the dinaciclib is at a: (a) dosage that is subtherapeutic for cancer treatment; (b) dosage that is less than 50%, 20% or 10% of therapeutic or conventional cancer dosage; (c) dosage that is less than 1 or 2 or 5 or 10 or 20 mg/m.sup.2; or (d) unit dosage form of less than 1, 2, 5, 10 or 20 mg.

26. The method of claim 1, wherein the hPER2 phosphorylating kinase inhibitor is dinaciclib.

27. The composition of claim 3, wherein the hPER2 phosphorylating kinase inhibitor is dinaciclib.

Description

BRIEF DESCRIPTION OF THE FIGURES

[0016] FIGS. 1a, 1b and 1c: Effects of kinase inhibitors discovered in the chemical screen for their abilities to modify the circadian rhythm of U2OS cell. (a) IKBKB inhibitors. The concentration of all the inhibitors was 10 M, n=5. (b) IKBKE inhibitors. The concentration of the inhibitors was as follow: Amelxanox, 15 M, n=4; Cayl0576, 15 M, n=4; BX795, 0.3 M, n=4 (c) CDKS inhibitors. The concentration of the inhibitors was as follow: dinaciclib, 10 nM, n=4; Cdk/Crk inhibitor, 10 nM, n=4; Cdk1/5 inhibitor, 10 M, n=4. Dinaciclib caused the most dramatic shift in the phase of the circadian clock.

DETAILED DESCRIPTION OF THE INVENTION

[0017] The detailed descriptions, particular embodiments and examples are provided by way of illustration and not by way of limitation. Those skilled in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results. All publications, patents, and patent applications cited herein, including citations therein, are hereby incorporated by reference in their entirety for all purposes.

[0018] Unless contraindicated or noted otherwise, in these descriptions and throughout this specification, the terms a and an mean one or more, the term or means and/or and polynucleotide sequences are understood to encompass opposite strands as well as alternative backbones described herein. Furthermore, genuses are recited as shorthand for a recitation of all members of the genus; for example, the recitation of (C1-C3) alkyl is shorthand for a recitation of all C1-C3 alkyls: methyl, ethyl and propyl, including isomers thereof.

[0019] The disclosure provides methods and compositions for modulating, preferably phase shifting, circadian rhythm.

[0020] The disclosure provides a method for modulating, preferably phase shifting, circadian rhythm, comprising administering to a subject in need thereof an hPER2 phosphorylating kinase inhibitor.

[0021] The disclosure provides a compound for use in a subject in need thereof, or in the manufacture of a medicament, to treat jet lag, shift-work or age-related sleep disturbances, wherein the compound is an hPER2 phosphorylating kinase inhibitor.

[0022] The disclosure provides composition comprising (a) an hPER2 phosphorylating kinase inhibitor, and (b) a different medicament for treating jet lag, shift-work or age-related sleep disturbances.

[0023] In one or more embodiments:

[0024] the kinase is selected from: CDK5, PRKACB, PRKG1, IKBKB, TSSK2 and IKBKE;

[0025] the kinase and inhibitor are selected from: (a) CDK5 and Dinaciclib , Cdk/crk inhibitor, Roscovitine or Indirubin-3monoxime-5-sulphonic acid, 9-Cyanopaullone; (b) IKBKB and Ikk2 inhibitor iv, Ikk2 inhibitor v, Ikk2 inhibitor vi or AS602868; and (c) IKBKE and Cay105765;

[0026] the inhibitor is in unit dosage form, preferably enteral (e.g. oral);

[0027] the inhibitor and medicament are copackaged or coformulated, preferably in unit dosage form, preferably enteral;

[0028] the medicament is caffeine, melatonin, zolpidem, eszopiclone, zaleplon or triazolam;

[0029] the subject is a person exposed or determined to be at risk of exposure to jet lag, shift-work or age-related sleep disturbances; and/or

[0030] the method further comprises the antecedent step of determining the subject is exposed or at risk of exposure to jet lag, shift-work or age-related sleep disturbances.

[0031] The disclosure provides a method of detecting a modulator of a mammalian intracellular clock comprising: (a) contacting a kinase with a compound and detecting a resultant inhibition of the kinase; and (b) contacting the mammalian clock with the compound and detecting a resultant modulation of the clock.

[0032] In one or more embodiments the kinase assay is in vitro or cell-based, and the clock assay is cell- or animal-based.

[0033] The disclosure provides a method of modulating circadian rhythm comprising administering to a subject in need thereof an effective amount of dinaciclib.

[0034] The disclosure provides a compound, dinaciclib, for use in a subject in need thereof, or in the manufacture of a medicament, to treat jet lag, shift-work or age-related sleep disturbances.

[0035] The disclosure provides a composition comprising dinaciclib, and a different medicament for treating jet lag, shift-work or age-related sleep disturbances.

[0036] In one or more embodiments:

[0037] the dinaciclib is at a: (a) dosage that is subtherapeutic for cancer treatment; (b) dosage that is less than 50%, 20% or 10% of therapeutic or conventional cancer dosage; (c) dosage that is less than 1 or 2 or 5 or 10 or 20 mg/m.sup.2; or (d) unit dosage form of less than 1, 2, 5, 10 or 20 mg;

[0038] the dinaciblib is in unit dosage form, preferably enteral (e.g. oral);

[0039] the dinaciblib and medicament are copackaged or coformulated, preferably in unit dosage form, preferably enteral;

[0040] the medicament is caffeine, melatonin, zolpidem, eszopiclone, zaleplon or triazolam;

[0041] the subject is a person exposed or determined to be at risk of exposure to jet lag, shift-work or age-related sleep disturbances; and/or

[0042] the method comprises the antecedent step of determining the subject is exposed or at risk of exposure to jet lag, shift-work or age-related sleep disturbances.

[0043] In one or more embodiments, the hPER2 phosphorylating kinase inhibitor is dinaciclib.

Dinaciclib Formulation and Administration

[0044] Dinaciclib, formulations and administration are readily empirically determined or otherwise known in the art, e.g. U.S. Pat. No. 7,119,200; US20160193334; WO 2015130585: Unless otherwise indicated, references below to dinaciclib also include pharmaceutically acceptable salts thereof. For preparing dinaciclib pharmaceutical compositions, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent dinaciclib. Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania. Liquid form preparations of dinaciclib include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration. Aerosol preparations of dinaciclib suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen. Also included are solid form preparations of dinaciclib that are intended to be converted, shortly before use, to liquid form preparations of dinaciclib for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions. Dinaciclib may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose. Dinaciclib may also be delivered subcutaneously. The pharmaceutical preparation can be in unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of dinaciclib, e.g., an effective amount to achieve the desired purpose. The quantity of dinaciclib in a unit dose of preparation may be varied or adjusted from about 1 mg to about 100 mg, more specifically from about 1 mg to about 50 mg, more specifically from about 1 mg to about 25 mg, according to the particular application. The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.

Examples

[0045] Drugs regulating the circadian rhythm are desired to treat jet-lag, shift work-related problems and circadian-related sleep disorders in diseased or aging populations. Because the circadian clock involves protein phosphorylation, we first performed a screen for human kinases capable of phosphorylating fragments of the human Period 2 (hPER2) protein, leading to the findings of 6 kinases previously unknown for PER phosphorylation. We then performed a screen of kinase inhibitors for functional regulation of the circadian rhythm in cultured human cells. Several inhibitors were found to either lengthen or shorten the period, while one, dinaciclib, significantly shifted the phase of the circadian clock in a dose- and phase-dependent manner: up to 8.1720.2194 hours (h) (meanSEM, n=4). Dinaciclib could shift the phase of the superchiasmatic nucleus (SCN), the master clock in the mouse brain. A single injection of dinaciclib into mice significantly improved adjustment in a jet lag paradigm with 6 h phase advancement. Thus, coupling chemical and biological screens effectively reveals small molecules of applications in clock shifting.

A Screen for Kinases Phosphorylating hPER2

[0046] To find kinases for hPER2, we subcloned and cotransfected cDNAs encoding kinases with different fragments of hPER2 in HEK293T cells. 288 protein kinases were successfully tested in our system. Phosphorylation of hPER2 was detected during the screen by the phos-tag which could bind to organic phosphate in proteins to delay their migration in sodium dodecyl sulfate-polyacrylaminde gel electrophoresis (SDS-PAGE) (Kinoshita et al., 2006). We divided the hPER2 with a molecular weight more than 130 kilodaltons (kD) into six fragments, each with a molecular weight between 20-30 kD. This was intended to increase the sensitivity of phosphorylation detection by gel-shift, and to separate the interference of phosphorylation on different sites. Because Fragments 771-1000 and 979-1240 showed multiple bands in HEK293T cells, our screen was focused on the remaining 4 fragments.

[0047] The screen uncovered zero kinase phosphorylating Fragment 1-200, one kinase phosphorylating Fragment 150-400, three kinases phosphorylating Fragment 328-556 and five kinases phosphorylating Fragment 556-771. Results from the screen were validated and that the gel shift was due to phosphorylation was confirmed by phosphatase treatment. One kinase phosphorylated both Fragment 328-556 and Fragment 556-771, while CSNK1D and CSNK1E have been previously identified (Akashi et al., 2002; Eide et al., 2005; Toh et al., 2001; Vanselow et al., 2006; Xu et al., 2005; Xu et al., 2007). This left us with 6 newly identified hPER2 phosphorylating kinases. Only one kinase, CDK5, was found to phosphorylate Fragment 150-400. PRKACB, PRKG1 and IKBKB can phosphorylate Fragment 328-556. PRKACB, TSSK2, IKBKE, CSNK1D and CSNK1E phosphorylate Fragment 556-771.

[0048] Effects of kinase inhibitors on the circadian rhythm of cultured human cells We tested inhibitors of newly found kinases for their potential regulation of circadian rhythm in U2OS cells expressing Per2-luciferase which faithfully reported the circadian clock (Zhang et al., 2009). We did not detect any effect of PRKACB and PRKG1 inhibitors on circadian rhythm. Effects of CDKS, IKBKB and IKBKE inhibitors are shown in FIG. 1 and Table 1.

TABLE-US-00001 TABLE 1 Kinase Inhibitor Phenotype IKBKB Ikk2 inhibitor iv Period lengthening, 3.16 0.167 h Ikk2 inhibitor v Period lengthening, 1.84 0.192 h Ikk2 inhibitor vi Period lengthening, 1.25 0.149 h IKBKE Amelxanox N Cay10576 Period shortening, 0.3 0.060 h; phase delay Bx795 N CDK5 Dinaciclib Period shortening, 0.6 0.050 h; phase delay Cdk/crk inhibitor Period shortening, 0.5 0.074 h; phase delay Cdk1/5 inhibitor N

[0049] All IKBKB inhibitors tested here lengthened the period. Three inhibitors of IKBKE showed different effects: Amelxanox and BX795 had no detectable effect whereas Cayl0576 shortened the period by 0.3 h. Three inhibitors of CDKS also showed different effects. Interestingly, dinaciclib significantly shifted the phase of the circadian rhythm of U2OS cells.

Effects of Dinaciclib on the Circadian Rhythm of Human Cells

[0050] To further test the effect of dinaciclib, we used a cell line expressing Bmall-luciferase, which oscillated in a phase different from Per2-luciferase. The phase-shifting effect of dinaciclib was confirmed in Bmal1-luciferase cells, supporting that dinaciclib affected the circadian rhythm, rather than just the expression of one reporter gene specifically. When the timing of first peak of Per2-luciferase expression was used to calculate the extent of phase shift, dinaciclib was found to delay the peak by 9.408 h. When applied from the beginning of the assay, dinaciclib increased the amplitude by 1.78 fold and shortened the period by 0.6 h.

[0051] We examined the dosage response of dinaciclib on Per2-luciferase expressing cells. The effects of dinaciclib on phase shifting, amplitude and period length were all dosage dependent. The EC50 (the half maximal effective concentration) of dinaciclib for phase shifting was 8.363 nM.

[0052] The above experiments were conducted with the drug added to the culture media from the beginning. To investigate whether the timing of drug treatment affected the response, dinaciclib was added to Per2-luciferase expressing cells at different circadian time (CT). Dinaciclib delayed the phase when applied at CTO by 4.0920.9062 h (p<0.01, n=5), at CT6 by 7.5430.6185 h (p<0.001, n=5) and at CT12 by 5.8080.5455 h (p<0.0001, n=5). However, the circadian phase was advanced by 1.70.81 h if dinaciclib was introduced at CT18. In summary, dinaciclib modification of the circadian rhythm is both dose- and phase-dependent.

Effect of Dinaciclib on the Circadian Rhythm in the SCN

[0053] U2OS cells are just cultured cells, while the SCN is the master clock in mammals. We dissected the SCN from mice expressing the Per2::Luciferase gene which faithfully reported the circadian rhythm (Yoo et al., 2004). SCN explants were cut into slices which maintained rhythmicity not only cell-autonomously but also in a cell-cell interaction dependent manner. Application of dinaciclib at CT12 advanced the phase of SCN explants by 2.4880.7391 h (p<0.01, n=8), whereas dinaciclib application at CTO or CT18 delayed the phase. Differences between SCN slices and isolated tissue culture cells may result from interaction among SCN cells required for synchronization.

[0054] Thus, dinaciclib can regulate the circadian rhythm in SCN slices containing the mammalian master clock. It significantly advanced the SCN phase when applied at CT12:00.

[0055] In Vivo Effect of Dinaciclib on a Jet Lag Paradigm of Mice

[0056] That dinaciclib can modify the phase of the circadian rhythm in cultured human cells and mouse SCN explants suggests the exciting possibility that dinaciclib can be a powerful drug to treat jet lag in intact animals.

[0057] After adult mice were placed in a light/dark (LD) cycle of 12L:12D (light on at CT 3:00, light off at CT15:00) for 11 days, dinaciclib (0.1 mg/kg body weight) was applied at CT20:00. At CT21:00, the LD cycle was advanced by 6 h (light on at CT21:00, light off at CT9:00), and the mice were kept in the new LD for 14 days.

[0058] Compared to the vehicle treated mice, mice treated with a single dose of dinaciclib adapted to the new LD cycle in a significantly shorter time. The 50% phase shift time (PS50) for the dinaciclib-treated group was 1.34 days while that for the control was 2.63 days (p<0.01). Thus, dinaciclib was effective in treating jet lag.

[0059] Our screen for kinases phosphorylating hPER2, a clock component, facilitated the screen for small molecules regulating the clock. The discovery of dinaciclib from the screens was extended by further analysis of its effects in cultured human cells, brain slices and intact mice.

[0060] Dinaciclib is an anti-cancer drug with no previous evidence to indicate that it could affect the circadian rhythm (Parry et al., 2010; Paruch et al., 2010). The facts that it has passed phase I and phase II of clinical trials and that the dose used for jet lag here is lower than that for cancer treatment support the possibility that dinaciclib is relatively safe (Fabre et al., 2014; Flynn et al., 2015; Gojo et al., 2013; Gorlick et al., 2012; Hu et al., 2015; Kumar et al., 2015; Mita et al., 2014; Mitri et al., 2015; Nemunaitis et al., 2013a; Stephenson et al., 2014; Zhang et al., 2012).

[0061] By screening 288 protein kinases, we have found 6 new kinases capable of phosphorylating hPER2. We tested typical inhibitors for their ability to modify the circadian rhythm in cultured human U205 cells. CDKS could phosphorylate hPER2 Fragment 150-400. CDKS is an atypical cyclin dependent kinase which is activated by P35 or P39 instead of cyclin (Dhavan and Tsai, 2001). Fragment 150-400 contains one PAS domain, which is for the transcriptional regulatory activity of PER proteins. However, there was a report that CDKS could phosphorylate the CLOCK protein (Kwak et al., 2013).

[0062] The immune system is under the control of circadian rhythm (Curtis et al., 2014; Scheiermann et al., 2013). In our kinase screen, IKBKB and IKBKE, two kinases known to be important in the immune system (Chen, 2012), could phosphorylate hPER2 fragments. Here we have also found that IKBKB inhibitors could lengthen the period of U205. The degradation of hPER2 requires the ubiquitination in the region 328-771 which is also phosphorylation dependent (Eide et al., 2005; Ohsaki et al., 2008). For example, the S662G mutation found in FASPS is in this region (Toh et al., 2001).

[0063] Dinaciclib is currently being investigated in clinical trials for a number of tumors, including refractory chronic lymphocytic leukemia (phase III). It potently and selectively inhibits CDKS, CDKS, CDK1 and CDK2 (Fabre et al., 2014; Flynn et al., 2015; Gojo et al., 2013; Gorlick et al., 2012; Guzi et al., 2011; Hu et al., 2015; Kumar et al., 2015; Mita et al., 2014; Mitri et al., 2015; Nemunaitis et al., 2013a; Nemunaitis et al., 2013b; Parry et al., 2010; Paruch et al., 2010; Stephenson et al., 2014; Zhang et al., 2012). Among the CDK inhibitors evaluated, dinaciclib is the most potent and has a unique kinase selectivity profile, though it remains to be investigated which CDK is the endogenous target of dinaciclib for its modification of the circadian rhythm. Our work indicates that regulators of kinase activities can provide effective and safe modifiers of the circadian rhythm, alleviating problems associated with not only jet lag, but also shift-work and age related sleep disturbances.

Mouse Jet Lag Assay

[0064] The tip of the cannula was inserted stereotaxically to the lateral ventricular of mice. After surgery, mice were returned to the home cage under a LD cycle (light on at CT3:00, light off at CT15:00) for 7 days before video recording of mouse activities began. After another four days, at CT 20:00, Dinaciclib dissolved in 20% hydroxypropyl--cyclodextran (Parry et al., 2010) (at the concentration of 5 mg/ml, at the speed of 0.51/min) or vehicle alone was pumped into the brain to achieve the total amount of 0.1 mg/kg of body weight by the UltraMicroPump III under the help of Micro4 Controller. At CT21:00 of the same day, the LD cycle was shifted to light on at CT21:00, light off at CT9:00, which was 6 hrs advanced. Mice were kept in the new LD for 14 days. Data was processed and moving distance/30 s was calculated.

Kinases

[0065] CDKS (cyclin-dependent kinase 5); PRKACB (protein kinase cAMP-activated catalytic subunit beta); PRKG1 (Protein kinase cGMP-dependent, Type 1); IKBKB (also IKK2)-Inhibitor of nuclear factor kappa-B kinase subunit beta; IKBKE (Inhibitor of nuclear factor kappa-B kinase subunit epsilon); TSSK2 (testis specific serine kinase 2).

Kinase Inhibitors

[0066] Dinaciclib, (2-R2S)-1-[3-ethyl-7-R1-oxidopyridin-1-ium-3-yemethylaminolpyrazolo[1,5-alpyrimidin-5-yl]piperidin-2-yl]ethanol), Amelxanox: (2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid), Cdk1/5 inhibitor (3-Amino-1H-pyrazolo[3 ,4-b]quinoxaline), Cdk/Crk inhibitor: (1-(2,6-dichlorophenyl)-6-[[4-(2-hydroxyethoxy)phenyl]methyl]-3-propan-2-yl-2H-pyrazolo[3,4-d]pyrimidin-4-one), IKK-2 inhibitor IV (TPCA-1, or 2-(carbamoylamino)-5-(4-fluorophenyl)thiophene-3-carboxamide), IKK-2 inhibitor V (IMD 0534, or N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide), IKK-2 inhibitor VI (2-[(aminocarbonyl)amino]-5 -phenyl-3-thiophenecarboxamide)), Cayl0576 (5-(5,6-dimethoxybenzimidazol-1-yl)-3-[(2-methylsulfonylphenyemethoxy]thiophene-2-carb onitrile), BX795 (N-[3-[[5-iodo-4-[3-(thiophene-2-carbonylamino)propylamino]pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide), KT5720 (Hexyl 6-hydroxy-5-methyl-13-oxo-5,6,7,8,14,15-hexahydro-13h-5,8-epoxy-4b,8a,14-triazadibenzo[b,h]cycloocta[1,2,3,4-jkl]cyclopenta[e]-as-indacene-6-carboxylate), Rp-cAMPS ((4aR,6R,7R,7aS)-6-(6-aminopurin-9-yl)-2-oxido-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-fu ro[3,2-d][1,3,2]dioxaphosphinin-7-ol; triethylazanium), KT5823 (9-methoxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8,11-epxoy-1H,8H,11H-2,7b-1 1a-triazadibenzo(a,g)cycloocta(cde)-trinden-1-one), Rp-8-Br-PET-cGMPS (sodium; 3-[(4aR,6R,7R,7aS)-7-hydroxy-2-oxido-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-fur 0[3,2-d][1,3,2]dioxaphosphinin-6-yl]-2-bromo-6-phenyl-5H-imidazo[1,2-a]purin-9-one).

REFERENCES

[0067] Akashi, M., et al. (2002). Mol and Cellular Biol 22, 1693-1703. [0068] Allada, R., et al. (2001). S. Annu Rev Neurosci 24, 1091-1119. [0069] Andreani, T. S., et al. (2015). Sleep medicine clinics 10, 413-421. [0070] Asher, G, and Sassone-Corsi, P. (2015). Cell 161, 84-92. [0071] Badura, L., et al. (2007). J Pharmacol and Exper Therapeutics 322, 730-738. [0072] Baker, C. L., et al. (2012). FEMS microbiology reviews 36, 95-110. [0073] Bass, J., and Takahashi, J.S. (2010). Science 330, 1349-1354. [0074] Blau, J. (2008). Genes & development 22, 1737-1740. [0075] Bunger, M. K., et al. (2000). Cell 103, 1009-1017. [0076] Cao, R., et al. (2013). Neuron 79, 712-724. [0077] Chen, Z., et al. PNAS USA 109, 101-106. [0078] Chen, Z., et al. (2013). Cellular and mol life sciences 70, 2985-2998. [0079] Chen, Z. J. (2012). Immunological reviews 246, 95-106. [0080] Chiu, J. C., Ko, H. W., and Edery, I. (2011). Cell 145, 357-370. [0081] Chiu, J. C., et al. (2008). Genes & development 22, 1758-1772. [0082] Chong, S .Y., et al. (2012). Trends in genetics 28, 598-605. [0083] Crane, B. R., and Young, M. W. (2014). Annual review of biochem 83, 191-219. [0084] Curtis, A. M., et al. (2014). Immunity 40, 178-186. [0085] Cyran, S. A., et al. (2005). J of Neurosci 25, 5430-5437. [0086] Dhavan, R., and Tsai, L. H. (2001). Nat Rev Mol Cell Bio 2, 749-759. [0087] Dibner, C., et al. (2010). Annual review of physiology 72, 517-549. [0088] Edery, I., et al. (1994). PNAS USA 91, 2260-2264. [0089] Eide, E. J., et al. (2005). Molecular and cellular biology 25, 2795-2807. [0090] Etchegaray, J. P., et al. (2009). Mol cellular biolo 29, 3853-3866. [0091] Fabre, C., et al. (2014). Cancer chemother and pharmacol 74, 1057-1064. [0092] Flynn, J., et al. (2015). Leukemia 29, 1524-1529. [0093] Gallego, M., et al. (2006). The Biochemical J 399, 169-175. [0094] Gallego, M., and Virshup, D. M. (2007). Nat Rev Mol Cell Bio 8, 139-148. [0095] Garbe, D. S., et al. (2013). Plos Genet 9, e1003749. [0096] Gekakis, N., et al. (1998). Science 280, 1564-1569. [0097] Gojo, I., Sadowska, M., et al. (2013). Cancer chemother and pharmacol 72, 897-908. [0098] Gorlick, R., et al. (2012). Pediatr Blood Cancer 59, 1266-1274. [0099] Griffin, E. A., et al. (1999). Science 286, 768-771. [0100] Guzi, T. J., et al. (2011). Mol Cancer Ther 10, 591-602. [0101] Hall, J. C. (2003). Adv Genet 48, 1-280. [0102] Hardin, P. E., Hall, J. C., and Rosbash, M. (1990). Nature 343, 536-540. [0103] Hirota, T., and Kay, S. A. (2009). Chemistry & biology 16, 921-927. [0104] Hirota, T., et al. (2010). PLoS biology 8, e1000559. [0105] Hirota, T., et al. (2012). Science 337, 1094-1097. [0106] Hirota, T., et al. (2008). PNAS USA 105, 20746-20751. [0107] Hogenesch, J. B., et al. (1998). PNAS USA 95, 5474-5479. [0108] Hu, C., et al. (2015). Mol Cancer Ther 14, 1532-1539. [0109] Iitaka, C., et al. (2005). J Biol Chem 280, 29397-29402. [0110] Isojima, Y., et al. (2009). PNAS USA 106, 15744-15749. [0111] Johannessen, et al. (2010). Nature 468, 968-972. [0112] Kaasik, et al. (2013). Cell Metab 17, 291-302. [0113] Kennaway, D. J., et al. (2015). Mol and cellular biochem 398, 195-206. [0114] Kim, E. Y., et al. (2007). Mol and cellular biol 27, 5014-5028. [0115] Kinoshita, E., et al. (2006). Mol Cell Proteomics 5, 749-757. [0116] Kivimae, S., et al. (2008). PLoS biology 6, e183. [0117] Kloss, B., et al. (1998). Cell 94, 97-107. [0118] Kloss, B., et al. (2001). Neuron 30, 699-706. [0119] Ko, H. W., et al. (2010). J of Neurosci 30, 12664-12675. [0120] Kumar, S. K., et al. (2015). Blood 125, 443-448. [0121] Kume, K., et al. (1999). Cell 98, 193-205. [0122] Kwak, Y., et al. (2013). J Biol Chemi 288, 36878-36889. [0123] Langmesser, S., et al. (2009). PloS one 4. [0124] Lee, C., et al. (2001). Cell 107, 855-867. [0125] Lee, C., et al. (2004). Mol and cellular biol 24, 584-594. [0126] Lee, H. M., et al. (2011). PNAS USA 108, 16451-16456. [0127] Levine, J. D., et al. (1994). Neuron 13, 967-974. [0128] Li, Y., et al. (2011).Mol human reproduction 17, 42-56. [0129] Lin, J. M., et al. (2005). J Neurosci 25, 11175-11183. [0130] Lowrey, P. L., et al. (2000). Science 288, 483-492. [0131] Lowrey, P. L., et al. (2011). Genetics Of Circadian Rhythms 74, 175-230. [0132] Maier, B., et al. (2009). Genes & dev 23, 708-718. [0133] Maywood, E. S., et al. (2014). J of biological rhythms 29, 110-118. [0134] Mehra, A., et al. (2009). Trends in biochem sciences 34, 483-490. [0135] Meng, Q. J., et al. (2008). Neuron 58, 78-88. [0136] Mita, M. M., et al. (2014). Clinical breast cancer 14, 169-176. [0137] Mitri, Z., et al. (2015). Investigational new drugs 33, 890-894. [0138] Miyazaki, K., et al. (2003). Novartis Found symposium 253, 238-248; discussion 249. [0139] Miyazaki, K., et al. (2004). The Biochemical journal 380, 95-103. [0140] Mohawk, J. A., and Takahashi, J.S. (2011). Trends in neurosciences 34, 349-358. [0141] Nawathean, P., and Rosbash, M. (2004). Mol Cell 13, 213-223. [0142] Nawathean, P., et al. (2007). Mol and cellular biol 27, 5002-5013. [0143] Nemunaitis, J. J., et al. (2013a). J Transl Med 11, 259. [0144] Nemunaitis, J. J., et al. (2013b). J Transl Med 11. [0145] Nijhawan, D., et al. (2003). Genes & development 17, 1475-1486. [0146] Nitabach, M. N. and Taghert, P. H. (2008). Current biol 18, R84-93. [0147] Ohlander, J., et al. (2015). Am J industrial med 58, 549-560. [0148] Ohsaki, K., et al. (2008). Journal of biochemistry 144, 609-618. [0149] Oshima, T., et al. (2015). Angew Chem Int Edit 54, 7193-7197. [0150] Panda, S., et al. (2002). Nature 417, 329-335. [0151] Parry, D., et al. (2010). Mol Cancer Ther 9, 2344-2353. [0152] Parsons, M. J., et al. (2015). Int J Obes (Lond) 39, 842-848. [0153] Paruch, K., et al. (2010). ACS medicinal chemistry letters 1, 204-208. [0154] Preitner, N., et al. (2002). Cell 110, 251-260. [0155] Price, J. L., et al. (1998). Cell 94, 83-95. [0156] Reed, S. E., et al. (2006). J Virol Methods 138, 85-98. [0157] Reischl, S., and Kramer, A. (2011). FEBS letters 585, 1393-1399. [0158] Reischl, S., et al. (2007). J biological rhythms 22, 375-386. [0159] Reppert, S. M., and Weaver, D. R. (2001). Annual review of physiology 63, 647-676. [0160] Reutrakul, S., and Knutson, K. L. (2015). Sleep medicine clinics 10, 455-468. [0161] Roenneberg, T., et al. (2012). Current biology : CB 22, 939-943. [0162] Sathyanarayanan, S., et al. (2004). Cell 116, 603-615. [0163] Sato, T. K., et al. Neuron 43, 527-537. [0164] Savelyev, S. A., et al. (2011). Journal of visualized experiments [0165] Scheiermann, C., et al. (2013). Nature reviews Immunology 13, 190-198. [0166] Schernhammer, E. S., et al. (2003). J Natl Cancer Inst 95, 825-828. [0167] Schmutz, I., et al. (2011). PloS one 6, e21325. [0168] Shanware, N. P., et al. (2011). J biol chem 286, 12766-12774. [0169] Shearman, L. P., et al. (2000). Science 288, 1013-1019. [0170] Shearman, L. P., et al. (1997). Neuron 19, 1261-1269. [0171] Shigeyoshi, Y., et al. (1997). Cell 91, 1043-1053. [0172] Shirogane, T., et al. (2005). J biological chemistry 280, 26863-26872. [0173] Sigurdardottir, L. G, et al. (2012). Cancer epidemiol, biomarkers & preven 21, 1002-1011. [0174] Solt, L. A., et al. (2012). Nature 485, 62-68. [0175] Sprouse, J., et al. (2010). Psychopharmacology 210, 569-576. [0176] Sprouse, J., et al. (2009). Psychopharmacology 204, 735-742. [0177] Stephenson, J. J., et al. (2014). Lung cancer 83, 219-223. [0178] Sun, Z. S., et al. (1997). Cell 90, 1003-1011. [0179] Takahashi, J. S., et al. (2008). Nature reviews Genetics 9, 764-775. [0180] Takano, A., et al. (2004). J Biol chem 279, 32578-32585. [0181] Tei, H., et al. (1997). Nature 389, 512-516. [0182] Toh, K. L., et al. (2001). Science 291, 1040-1043. [0183] Tsuchiya, Y., et al. (2009a). Science signaling 2. [0184] Tsuchiya, Y., et al. (2009b). Science signaling 2, ra26. [0185] Tynes, T., et al.1996). Cancer causes & control 7, 197-204. [0186] Uchida, Y., et al. (2012). J Biol chemistry 287, 8318-8326. [0187] Ueda, H. R., et al. (2002). Nature 418, 534-539. [0188] van der Horst, G. T. J., et al. (1999). Nature 398, 627-630. [0189] Vanselow, K., et al. (2006). Genes & development 20, 2660-2672. [0190] Vielhaber, E., et al.2000). Mol and cellular biol 20, 4888-4899. [0191] Vitaterna, M. H., et al. (1999). PNAS USA 96, 12114-12119. [0192] Walton, K. M., et al. (2009). J pharmacol and exp therapeutics 330, 430-439. [0193] Welsh, D. K., et al. (2010). Annual review of physiology 72, 551-577. [0194] Xu, Y., et al. (2005). Natu re 434, 640-644. [0195] Xu, Y., et al. (2007). Cell 128, 59-70. [0196] Yamaguchi, Y., et al. (2013). Science 342, 85-90. [0197] Yoo, S. H., et al. (2004). PNAS USA 101, 5339-5346. [0198] Zhang, D., et al. (2012). Cancer chemotherapy and pharmacol 70, 891-898. [0199] Zheng, B., et al. (1999). Nature 400, 169-173. [0200] Zheng, X., and Sehgal, A. (2012). Trends in neurosciences 35, 574-585. [0201] Zhou, M., et al. (2015). Mol Cell 60, 77-88. [0202] Zylka, M. J., et al. (1998). Neuron 20, 1103-1110.